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The discovery of miRNAs has revolutionized the way we examine the genome, RNA products, and the regulation of
transcription and translation. Their ability to modulate protein expression through mRNA degradation and
translation repression resulted in avid scientific interest in miRNAs over the past decade. This research has led to
findings that indicate miRNAs can regulate an array of cellular functions such as cellular apoptosis, proliferation,
differentiation, and metabolism. Specifically, the capability of miRNAs to finely-tune gene expression naturally lends
itself to immune system regulation which requires precise control for proper activity. In fact, abnormal miRNAs
expression is often seen with inflammatory disorders like rheumatoid arthritis, systemic lupus erthematosus,
experimental autoimmune encephalomyelitis, and inflammatory cancers. As a result, research investigating miRNAs
modulation of immune cell proliferation, differentiation, and cellular signaling has yielded fruitful results. Specifically,
in this review, we will examine the impact of miRNAs on toll-like receptor (TLRs) and interleukin-1β (IL-1β) signaling,
which are integral in the proper functioning of the innate immune system. These signaling pathways share several
key downstream signaling adaptors and therefore produce similar downstream effects such as the production of
pro-inflammatory cytokines, chemokines, and interferons. This review will examine in depth the specific interactions
of miRNAs with receptors, adaptor molecules, and regulator molecules within these cellular pathways. In addition,
we will discuss the modulation of miRNAs’ expression by TLR and IL-1R signaling through positive and negative
feedback loops.
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The existence of a molecular system capable of orches-
trating the expression of numerous proteins was postu-
lated by researchers for some time; the discovery of
microRNAs (miRNAs) confirmed this hypothesis. This
breakthrough revolutionized the way we examine the
genome organization, RNA products, as well as mRNAs
translational and degradation. Originally discovered in
1993, it soon became evident that miRNAs are abundant
and often conserved across species. Even more striking is
their ability to modulate a wide range of cellular func-
tions, such as apoptosis, proliferation, differentiation,
and metabolism. In addition to cellular activities,
miRNAs were also found to be capable of regulating
a broad spectrum of systemic functions like inflammatory* Correspondence: xfyang@temple.edu
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reproduction in any medium, provided the orresponses. The nature of miRNAs function, to finely-tune
protein expression through mRNAs degradation and
translation repression, naturally lends itself to immune
system regulation which requires precise control for
proper activity. Therefore, it is not coincidence that altered
miRNAs expression is often associated with progression
and remission of inflammatory disorders like rheumatoid
arthritis, systemic lupus erythematosus, and experimental
autoimmune encephalomyelitis. Ensuing research investi-
gating miRNAs modulation of immune cell proliferation,
differentiation, activity, and cellular signaling has yielded
fruitful results. Specifically, in this review, we will examine
the impact of miRNAs on the integral toll-like receptor
(TLR) and interleukin-1 receptor (IL-1R) inflammatory
signaling pathways. Both pathways share several key
signaling adaptors and therefore induce similar cellu-
lar responses when activated. Together they play an
indispensable role in the innate immune system by
triggering the production of pro-inflammatory proteinstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 miRNAs processing and maturation. Transcribed into a
primary transcript of several hundred base-pairs in length, primary
miRNAs may undergo editing by adenosine deaminases. Following
this, the miRNAs transcript is cleaved by the RNase II enzyme Drosha
and then exported to the cytoplasm from the nucleus. Within the
cytoplasm the precursor miRNAs transcript is further cleaved by the
RNase-III enzyme Dicer. The resulting duplex is then unwound by
RNA helicases resulting in mature miRNAs production.
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interactions of miRNAs with receptors, adaptor molecules,
and regulator molecules within these cellular pathways will
be examined in depth. Finally, the modulation of miRNAs
expression by TLR and IL-1R signaling will be
reviewed.
miRNAs
Prior to recent breakthroughs, it was believed that the
majority of DNAs were transcribed to mRNAs and then
translated into proteins. The remaining RNAs not coding
for protein were either ribosomal RNAs, transfer RNAs,
or perceived as “junk” with little to no pertinent func-
tion. In 2003, at the completion of the Human Genome
Project, between 20,000 – 25,000 protein coding genes
were identified from the 3 billion nucleotide base-pairs
of the human genome. Puzzling was the fact that protein
coding sequences only accounted for approximately 2%
of the total genome [1]. These findings made it hard to
believe that such a large majority of the genome was
“junk”. Partial enlightenment came with the discovery of
additional classes of non-coding RNAs (ncRNAs).
Defined simply, ncRNAs are any RNAs that are not
translated into protein. Functional applications of these
once over looked segments of RNAs include but are not
limited to cell metabolism, cell proliferation, cell differ-
entiation, protein secretion, and embryonic development
[2-5]. Several classes of ncRNAs exist including transfer
RNAs (tRNAs), small nuclear RNAs (snRNAs), riboso-
mal RNAs (rRNAs), small interfering RNAs (siRNAs),
and microRNAs (miRNAs). Possibly the most intriguing
class of ncRNAs is miRNAs whose discovery dramatic-
ally revised the dogma that RNAs simply act as a tem-
plate for protein translation. Mature miRNAs are
capable of post-transcriptional gene silencing through
base-pair interactions with mRNAs and therefore can
regulate protein expression. Thus far, over 1,000 miR-
NAs have been identified which are predicted to regulate
up to 30% of protein encoding genes.
From a biogenesis standpoint, miRNAs are transcribed
in similar fashion to mRNAs encoded by protein coding
genes. Their genomic sequence can be found within
introns of other genes or can be encoded independently.
Once transcribed into primary miRNAs, which can be
several hundred base-pairs in length, the transcripts may
undergo editing by adenosine deaminases. This post-
transcriptional modification leads to the exchange of ad-
enosine with inosine which results in an alteration to the
transcript’s base-pairing, potentially leading to structural
changes. After this, the transcripts undergo processing
by the RNase II enzyme Drosha within the nucleus.
Cleaved to a length of approximately 70 base-pairs, these
precursor miRNAs are then exported from the nucleus
to the cytoplasm by exportin 5 and Ran-GTP. Withinthe cytosol the precursor miRNAs are further cleaved by
the RNase-III processing enzyme Dicer to their mature
length of 18–23 base-pairs. Upon dicer cleavage,
duplexes formed by the hairpin structure of the precur-
sor miRNAs are unwound by RNA helicases (Figure 1).
A single strand then enters the RNA-induced silencing
complex (RISC), which then facilitates miRNAs-directed
mRNAs translation repression or cleavage [6,7].
miRNAs:mRNAs interactions usually occur at the 3’
untranslated region (3’UTR) of mRNAs through imper-
fect Watson and Crick base-pairing. Noteworthy is that
imperfect pairing facilitates the possibility of multiple
binding sites for a single miRNA with a particular
mRNA. It also promotes promiscuity allowing for mul-
tiple mRNA partners for a single miRNA. However, the
molecular details of how miRNAs specifically target
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Despite this, several structural features which promote
miRNAs:mRNAs binding have been elucidated. It has
been determined that a region of 6–8 nucleotides, at
residues 2–7 on the 5’ end of miRNAs, is critical in
establishing miRNAs:mRNAs interactions and is com-
monly referred to as the “seed region” [8]. The signifi-
cance of this region is supported by the high level of
conservation at the 5’ ends of related miRNAs [9-12].
Meanwhile, the 3’ ends of miRNAs have been demon-
strated to participate in base-pairing as well. With the
ability to contribute to mRNAs interference, it is postu-
lated that while the 5’ end is required for target identifi-
cation, the 3’ end is responsible for modulating
repression strength [8,9,13]. Specifically, additional bind-
ing in the 3’ end of miRNAs with emphasis on nucleo-
tides 12–17 demonstrated augmented miRNAs
repression [8]. Other structural features have also been
accredited with facilitating miRNAs efficacy. For ex-
ample, AU richness proximally flanking the seed region
binding site has been shown to contribute to miRNAs ef-
ficacy, although these contributions quickly diminish
with distance from the binding site [8,14,15]. In addition,
the location of the miRNAs binding site within the 3’
UTR of mRNAs also plays a role in determining miRNAs
functionality. Sites situated near either end of the 3’UTR
of mRNAs have been reported to demonstrate greater
activity compared to sites that reside in the center of the
3’UTR region of mRNAs. It should be noted that this ef-
fect was more pronounced in longer 3’UTRs and that
site-conservation in these areas is greater than centrally
located sequences. However, sites located to close the
open reading frame or within 15 nucleotides of the stop
codon have been found to have low binding affinity
[8,11,16,17]. Aside from these structural features, it has
also been revealed that proximal miRNAs binding sites
tend to interact synergistically while multiple sites atFigure 2 miRNAs endonucleic cleavage. Upon miRNAs-directed associat
intrinsic enzymatic protein Argonaute 2 can induce endonucleic cleavage.
Argonaute 2. The mRNAs fragments then undergo exonuclease degradatiodistance behave independently with an additive affect
[8,9,13,18,19]. This synergistic affect potentially allows
for efficient protein regulation with minimal increase in
miRNAs cellular levels.
As mentioned previously, miRNAs can biologically
cause mRNAs cleavage or translation repression.
miRNAs-directed endonuclease cleavage of mRNAs is
functionally carried out by the highly conserved family of
Argonaute proteins [20]. The presence and variety of
Argonaute proteins is cell type- and species-specific,
allowing for the possible formation of miRNA-specific
RISC complexes [21]. In humans, four Argonaute sub-
family members exist, although Argonaute 2 (Ago2) is
the only member with intrinsic enzymatic activity
[22,23]. Approximately 100 kDa in size, Argonaute pro-
teins are basic in nature and contain a PAZ and PIWI
domain [24]. The PAZ domain has shown affinity for
single- and double-stranded RNAs and therefore allows
Argonaute proteins to bind to the stem-loop structure of
pri-miRNAs during biogenesis and to mature miRNAs in
the RISC complex [25-28]. Meanwhile, the highly con-
served PIWI domain contains an RNase H domain which
provides certain Argonaute proteins their splicing activ-
ity. This theory is supported by the fact that RNase H sli-
cing results in a 3’ overhang which is associated with
miRNAs-directed cleavage (Figure 2) [20,29-31]. Slicing
typically occurs under conditions of perfect base-pairing
between miRNAs and mRNAs although some mis-
matches can be tolerated [32-34]. It should be noted,
that perfect base-pairing does not guarantee endonucleo-
lytic cleavage [35]. This suggests that additional RISC-
associated molecules are needed for the cleavage of cer-
tain mRNAs. Following cleavage, mRNA fragments
undergo standard degradation through either conserved
or eukaryotic-specific pathways. Independent of the
pathway utilized, initial removal of the 3’poly (A) tail is
followed by exonuclease degradation [36,37].ion of the RNA-induced silencing complex (RISC) with mRNAs, the
This is possible as a result of the RNase H activity of the PIWI domain of
n.
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lized by miRNAs. Described as early as 1993, several
studies have been conducted with a range of miRNAs
that demonstrate a reduction in protein expression in
the midst of unwavering or minimally altered mRNAs
levels [35,38-42]. Despite this knowledge, the exact
mechanism of how the repression is facilitated is un-
known. It is postulated that this suppression is most
likely a by-product of an alteration to translation
initiation or post-initiation (Figure 3). In fact, ade-
quate amounts of data exist to support both mechanisms
[43-50]. It appears that miRNAs which instigate transla-
tion initiation repression require the presence of Ago-2
[51,52]. Although the exact biochemical interactions of
these proteins have yet to be elucidated, it is known that
structurally Ago-2 contains a cap binding-link motif
similar to that of eukaryote translation initiation factor
4E (eIF4E), a critical protein in translation initiation
[53,54]. This fact, along with additional experimental
information, suggests that Ago-2 does in fact inter-
act directly with the cap or indirectly through asso-
ciated proteins [53]. It is logical to extrapolate that
RISC association with the cap, through Ago-2, wouldFigure 3 miRNAs translation repression. Typically, mRNAs is translated in
activity through blockade of translation initiation (middle) or post-initiation
proteins prevent the association of ribosomes with mRNAs and thereby tra
with the mRNAs but are incapable of completing translation either due to
miRNAs. In addition, post-initiation translation repression may occur due todramatically affect translation initiation and thereby re-
press translation.
Meanwhile, sedimentation studies conducted with
mRNAs under miRNAs repression yield results which
indicate the association of polysomes. This provides
evidence that particular miRNAs function through
post-initiation translational interference [48,49,55-58].
Furthermore, the activity of the associated polysomes
in translation was verified through puromycin-
sensitivity assays [58]. It can be postulated that two
mechanisms may be involved in post-initiation suppres-
sion. First, miRNAs association could result in elong-
ation interference leading to a dramatic reduction in
elongation rate. Second, the presence of miRNAs may
lead to premature ribosomal dissociation prior to the
completion of translation as a consequence of mRNAs
instability or physical impediment. Currently the exact
mechanism is unclear, which may indicate the possibil-
ity that different miRNAs subtypes exist. Whether ini-
tial or post-initial translation repression is utilized,
both would account for reductions in protein levels
amidst unwavering mRNAs expression witnessed
experimentally.to protein by ribosomes (above). However, miRNAs can inhibit this
translation (below). During translation initiation, repression by RISC
nslation. With post-initiation translation repression, ribosomes associate
premature disassociation or physical impediment by associated
diminished elongation rates as a result of the presence of miRNAs.
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The recent discovery of a class of evolutionarily-
conserved receptors has led to the re-examination of the
signaling and function of the innate immune system.
TLRs are a class of membrane-bound pattern recogni-
tion receptors that are capable of identifying particular
pathogen associated molecular patterns (PAMPs) and
danger associated molecular patterns (DAMPs). Initially
discovered in insects, the Toll receptor was determined
to play a function in innate immune protection against
fungal infections. Pursuit of Toll homologues in humans
revealed 11 members, which can identify a wide range of
ligands. As Type I integral membrane glycoproteins,
TLRs share significant cytoplasmic region homology with
interleukin-1 receptors (IL-1R). Within the cytoplasmic
tails of the TLRs/IL-1R is a highly conserved region of
approximately 200 amino acids referred to as the Toll/
IL-1R (TIR) domain [59]. This conserved sequence con-
tains three boxes - box 1 (FDAFISY), box 2 (GYKLC-
RD-PG), and box 3 (a conserved W surrounded by basic
amino acid residues). Boxes 1 and 2 are believed to be
involved in the binding of signaling proteins, whereas
box 3 is primarily thought to be involved in the
localization of the receptor [59]. Due to this homologous
TIR domain, both TLR/IL-1 receptors utilize a shared
downstream signaling pathway, which will be discussed
in detail later. However, unique extracellular domains
allow TLRs/IL-1 receptors to recognize different ligands.
The extracellular regions of TLRs contain leucine-rich
repeats which form a horseshoe shape and share no
homology with IL-1R. Despite the conservation of this
region among TLRs, individual receptors maintain the
capability of recognizing very different ligands [60].
TLR4 has been attributed with the recognition of several
factors including fibrinogen, mouse mammary-tumor
virus envelope proteins, taxol, respiratory syncytial virus
fusion proteins, heat shock proteins, and lipopolysac-
charide (LPS) while TLR3 can identify double-stranded
viral DNA [61-68]. The location of ligands recognized by
each TLR dictates whether the receptor is located on the
cellular membrane or intracellularly. For example, TLR4
ligands are located extracellularly and therefore this par-
ticular receptor is found on the cell membrane. In con-
trast, TLRs −3, -7, and −9 which recognize double-
stranded viral DNA, single-stranded RNA, and abnormal
nucleic acid motifs respectively, are logically located intra-
cellularly [69-71].
IL-1
The cytokine interleukin-1 (IL-1) was first discovered in
the early 1940s. Produced by active leukocytes and found
to induce fever, the protein was aptly named “pyrexin” or
“endogenous pyrogen” [72]. It later became evident that
this protein did more than induce fever as it mediated anarray of biological activities and played a key role in the
inflammatory process. Biologically, IL-1 is a potent in-
ducer of chemokines, other cytokines, adhesion mole-
cules, and inflammatory proteins. It soon became
evident that the effects of IL-1 were actually the cumula-
tive action of two cytokines, IL-1α and IL-1β [3,4]. Al-
though transcribed from two unique genes found
adjacent on chromosome 2, IL-1α and IL-1β share a
modest amino acid sequence homology of only 27% [5-
8]. Despite this, both have a comparable mature three-
dimensional structure [7,8]. This similarity allows both
IL-1α and IL-1β to bind to the same receptor, leading to
the activation of shared downstream mediators [73]. The
80 kDa receptor, IL-1R1, contains three extracellular im-
munoglobulin domains and an intracellular domain [31-
33]. As mentioned previously, the intracellular portion of
IL-1R1 contains a TIR domain and is the reason why it
is grouped in the interleukin-1 receptor/Toll-like recep-
tor superfamily. IL-1R1 interaction with IL-1 results in
the recruitment of a second receptor chain termed IL-1R
accessory protein (IL-1RAcP) [34]. Dimerization of IL-
1R with IL-1RAcP results in receptor activation.
MyD88-dependent signaling pathway
Following Toll-like/IL-1 receptor activation conform-
ational changes occur which trigger a shared down-
stream signaling cascade (Figure 4) [74]. Myeloid
differentiation primary-response protein 88 (MyD88) is
the first adaptor recruited to the activated receptor com-
plexes. Due to a carboxyl-terminal TIR domain, MyD88
can directly interact with TLRs/IL-1R through TIR-TIR
interactions. In fact, mice deficient of MyD88 have dis-
played an inability to produce IL-6 or tumor necrosis
factor-α (TNF-α) in response to exposure with known
TLR microbial ligands or IL-1, reaffirming the signifi-
cance of MyD88 in TLR/IL-1 signaling. It should be
noted that in the specific instances of TLR-2 and −4 sig-
naling the association of another TIR-domain containing
protein, MyD88 adaptor-like (MAL), facilitates the bind-
ing of MyD88. It is believed that the presence of the
electro-negative TIR domain of MAL is necessary for the
proximal association of the TIR-domains of TLR4 and
MyD88, which are both electro-positive [75]. Structur-
ally, MyD88 also contains an N-terminal death domain
which facilitates interactions with downstream adaptors
[76]. Specifically, IRAK1 and IRAK4, members of the
interleukin-1 receptor-associated kinase (IRAK) family,
also contain an N-terminal death domain and have a
serine/threonine-kinase domain which provides intrinsic
kinase function [77,78]. Following TLR/IL-1R activation
the intrinsic kinase function of IRAK1 is strongly
induced leading to the downstream activation of nuclear
factor κB (NF-κB) [77,79]. However, abrogation of IRAK1
kinase activity still results in NF-κB activation, mitigating
Figure 4 MyD88-dependent TLR/IL-1R signaling. TLR/IL-R activation leads to the association of MyD88 (myleoid differentiation
primary-response protein 88), which can be enhanced by the presence of MAL (MyD88 adaptor-like) (TLR4 signaling only). As a result, IRAK1 and
IRAK4 (interleukin-1 receptor-associated kinase) are recruited to the receptor. Following IRAK1 phosphorylation by IRAK4, TRAF6 (TNF receptor
associated factor 6) interacts with IRAK1. This leads to the dissociation and relocation of IRAK1, IRAK4, and TRAF6 to the plasma membrane. There,
interaction with the complex of TAK1 (TGF-β-activated kinase 1), TAB1 (TAK1-binding protein), and TAB2 leads to the relocation and association of
TAK1 to either the IKK (IκB kinase complex) complex or ASK1 (apoptosis signal-regulating kinase 1). Interface with ASK1 results in downstream
MAPK signaling leading to AP-1/ATF transcription factor activity, whereas interaction with IKK leads to IκB degradation and NF-κB transcription
factor activity.
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the deletion of IRAK1 results in reduced cytokine produc-
tion in response to LPS, a known TLR-4 ligand, and IL-1
[80,81]. This indicates a supporting role of IRAK1 in
TLR/IL-1 signaling. The selective deletion of IRAK4
on the other hand, completely alleviates IL-1-mediated
NF-kB activity, indicating its necessity for TLR/IL-1 sig-
naling [82]. Interestingly, it has been determined that
IRAK1 is a substrate of IRAK4 but not vice versa
[83]. Utilizing this information, one can surmise that
IRAK4 directly interacts with the adaptor MyD88 andthen interacts with IRAK1 leading to IRAK1 phosphoryl-
ation. This induces IRAK1’s kinase activity, causing autop-
hosphorylation and leads to a conformational change
which makes it suitable for further adaptor interactions
[74].
Containing six family members, the TNF receptor
associated factors (TRAFs) are a group of evolutionary
conserved adaptor molecules [84]. Structurally, TRAFs
contain a characteristic coiled-coil domain within the N-
terminus while the C-terminus functions as an interface
for upstream interactions and self-association [85].
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contains the binding motif P-X-E-X-X that is also found
three times within IRAK1. TRAF6 binding to IRAK1
leads to the dissociation of TRAF6, IRAK1, and IRAK4
[86]. This complex proceeds to the plasma membrane
where it interacts with the complex of transforming
growth factor-β (TGF-β)–activated kinase 1 (TAK1),
TGF-β-activated protein kinase 1-binding protein 1
(TAB1), and TGF-β-activated protein kinase 1-binding
protein 2 (TAB2). The mitogen-activated protein kinase
(MAPK) kinase kinase TAK1 is essential in IL-1 and
TNF-α-induced NF-κB activation [87]. TAB1 is capable
of boosting the activity of TAK1 while TAB2 acts as a fa-
cilitator of TAK1 activation by acting as an adaptor to
TAK1/TRAF6 association [88,89]. It should be noted
that a TAB2 deficiency does not result in impaired IL-1
and TNF-induced NF-κB activation [90]. This is most
likely explained by the discovery of TAB3, which is
believed to have TAB2 redundant activity. This hypoth-
esis was validated when transfection with small interfer-
ence RNA directed against both TAB2 and TAB3
resulted in abrogation of NF-κB activation induced by
IL-1 and TNF-α [91]. Once activated, TAK1 proceeds
to interface with the inhibitor of NF-κB (IκB) kinase
complex (IKK). This interaction leads to IKK activation
causing downstream phosphorylation of IκBs resulting in
their degradation. As a result, this frees NF-κB, a protein
comprised of two subunits p50 and p65, from IκB repres-
sion. This allows NF-κB to translocate to nucleus where
the transcription augmentation of NF-κB-dependent
pro-inflammatory genes occurs.
Aside from NF-κB activation induced by the TLR/IL-1
signaling just discussed, an alternative pathway can
be triggered midway through the signaling cascade by
both TLRs and IL-1R. This results in the activation of
p38 mitogen-activated kinases (p38), c-Jun N-terminal
kinases (JNKs), extracellular signal-regulated protein
kinases (ERKs), and the two transcription factors - acti-
vator protein-1 (AP-1) and activating transcription factor
(ATF) [92-94]. While the exact signaling cascade which
leads to the activation of these factors has yet to be
clearly defined, it is believed that following TRAF6-
induced activation, TAK1 associates with apoptosis
signal-regulating kinase 1 (ASK1/MAPKKK5) under cer-
tain circumstances instead of IKK as mentioned above
[95]. In fact, it has been reported that overexpressed
ASK1 can inhibit IL-1 induced NF-κB activation by com-
peting with TRAF6 for TAK1 [96]. Moreover, ASK1-
deficient mice were shown to be protected from LPS-
induced septic shock, demonstrating the significance of
the alternative pathway in innate immune responses [97].
Activation of ASK1 leads to the triggering of p38 and
JNK signaling pathways [98]. It should be noted that
ASK1-deficient mice only display impaired signaling toLPS and not to the TLR-3 and −9 ligands poly(I:C) or
CpG-DNA. Furthermore, impaired TLR-4 signaling
appeared to be related to p38 signaling and not JNK sig-
naling [97]. Taken together this may indicate TLR speci-
ficity or TLR-specific MAPKKK in p38 and JNK
signaling.
MyD88-independent signaling pathway
While mice deficient of MyD88 have displayed an inabil-
ity to produce IL-6 or TNF-α when exposed to TLR mi-
crobial ligands or IL-1, more extensive experimentation
with LPS resulted in delayed NF-kB activation and INF-β
production. These results indicated the existence of a
MyD88-independent pathway (Figure 5). It has been
shown that this alternative pathway activates interferon
regulatory factor-3 (IRF-3) and −7 (IRF-7), leading to the
induction of IFN-α and IFN-β and is also capable of propa-
gating NF-κB activation. While the MyD88-independent
pathway is the secondary pathway employed by TLR-4,
its activity has been found to act in conjunction with
the MyD88-dependent pathway in the production of pro-
inflammatory cytokines. Alternatively, the MyD88-
independent pathway is the sole signaling pathway utilized
by TLR-3. This is logical since TLR-3 recognizes double-
stranded RNA often associated with viruses which are
more effectively combated by IFN production as compared
to NF-κB mediators. It should be noted that IL-1 signaling
cannot facilitate this cascade.
Although the MyD88-independent signaling pathway
is less elucidated than the MyD88-dependent pathway,
some key players have been identified. Required for
interfacing with all TLRs is the presence of a TIR-
domain within the direct downstream adaptor protein.
To identify this protein, researchers relied on bioinfor-
matics which led to the discovery of TIR-domain-
containing adaptor protein inducing IFN-β (TRIF). It
was quickly established that TRIF mediates the MyD88-
independent pathway based on experimental results in
TRIF-deficient mice which displayed impaired IFN-β
production (IRF3) upon stimulation with TLR-3 and −4
ligands [99]. Signaling downstream of TRIF are two non-
canonical IKKs, IKKε and TBK1. Both have been shown
to activate NF-κB and IRF-3 [100-105].
Another TIR-domain containing protein, TRIF-related
adaptor molecule (TRAM), was also identified by in
silico studies [75]. Again, knockout mice were utilized to
identify the role of TRAM in TLR/IL-1 signaling. Experi-
mentation with IL-1β revealed no impairment of NF-κB
activation, JNK activation, or IL-6 production in TRAM
knockouts. This result indicated that TRAM was not
involved in the shared TLR/IL-1 MyD88-dependent sig-
naling pathway. This conclusion was further supported
when TRAM-deficient mice displayed normal immuno-
logical responses to ligands for TLR-2, -7, and −9, which
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exploration of the role of TRAM in MyD88-independent
signaling revealed that TLR-4 but not TLR-3 production
of IFN-β or other IFN-inducible genes were impaired in
TRAM-deficient mice [106]. This suggests an exclusivity
of TRAM in TLR-4-mediated MyD88-independent sig-
naling. Currently, it is believed that TRAM facilitates
TRIF binding with TLR-4 in a similar fashion as MAL in
MyD88/TLR-4 association.
Further examination in TRAM knockout mice revealed
that TLR-4-mediated NF-κB activation was impaired in a
time-dependent fashion. Initial NF-κB activation, 10–20
minutes following LPS treatment, was undeterred while
levels were diminished at 60–120 minutes when com-
pared with wild-type controls. Similarly, JNK activity was
also found to be limited in a time-dependent manner [106].
These findings indicate a divergent role between MyD88-
dependent and –independent signaling pathways. MyD88-
dependent signaling induces a rapid immunologicalFigure 5 MyD88-independent TLR signaling. Particular TLRs, like TLR3 an
leads to the association of TRIF (TIR-domain-containing adaptor protein ind
TRAM (TRIF-related adaptor molecule) also associates with the receptor to f
NF-κB-directed transcription occurs along with IFN-α/β production. Althoug
two non-canonical IKKs (inhibitor of NF-κB kinase complex), IKKε and TBK1
initiate both NF-κB and IRF-3 (interferon-3) activity. In addition to IRF-3, IRF-
to IFN-α/β production.response while MyD88-independent signaling triggers a
delayed response allowing for immune sustainability. To
ensure that the MyD88-dependent and –independent are
the only pathways utilized by TLR-4, MyD88/TRIF double
knockout mice were bred. In this model LPS-induced NF-
κB activation was completely abolished suggesting the ab-
sence of any further signaling cascades.
JAK2/STAT5/IL-6 signaling
IL-6, a known proinflammatory cytokine, is produced in
response to challenge with several TLR ligands and IL-1
signaling. However, the exact signaling required for
this induction has not been resolved; specifically, the
upstream signal transduction. It has been reported
that the NF-κB subunit, p50, can increase IL-6 expres-
sion. Furthermore, signal transducer and activator of
transcription 5 (STAT5) is activated by LPS treatment in
mouse monocyte/macrophage RAW cells and peritoneal
macrophages. A possible interaction between p50 andd TLR4, can initiate MyD88-independent signaling. Receptor activation
ucing IFN-β) protein. Specific to TLR4 signaling, the adaptor protein
acilitate TRIF binding. As a result of TRIF binding, downstream
h the exact signaling chronology is undetermined, it is known that
(TANK-binding kinase 1) are activated. As a result, theses IKKs can
7 is also known to be activated in the independent pathway leading
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immunoprecipitation assay in African green monkey kid-
ney fibroblast-like COS-7 cells. To determine the mech-
anism of IL-6 induction, a chromatin
immunoprecipitation assay was conducted and showed
that both p50 and STAT5 located to the promoter of IL-
6. Traditionally, functioning upstream of STATs are
Janus kinases (JAKs). In particular, JAK2 expression was
found to be augmented within 1–5 minutes following
LPS treatment in RAW cells. This finding, along with
comparative downstream effects following deletion of ei-
ther JAK2 or STAT5, indicates that both are involved in
this signaling pathway. Investigation of further upstream
signaling revealed that JAK2 could not associate
individually with either MyD88 or TLR-4 in co-
immunoprecipitation assays. However, JAK2 was found
to interact with the MyD88/TLR-4 complex. This evi-
dence suggests the existence of an unidentified adaptor
molecule that facilitates this interaction. Interestingly,
IL-6 has been demonstrated to induce suppressor of
cytokine signaling 1 (SOCS1), a known negative regula-
tor of cytokine signaling. The role of SOCS in TLR/IL-1
signaling will be discussed in-depth in the following
section [107].
Endogenous TLR/IL-1 signaling regulators
Hyper-activation of immune signaling pathways can ser-
iously impact overall health, leading to a wide variety of
chronic inflammatory and autoimmune illnesses. Each
adaptor molecule within the TLR/IL-1 signaling pathway
is under stringent control via phosphorylation, physical
interactions, conformational changes, as well as ubiquitin
and proteasomal degradation. Furthermore, there are
regulatory proteins designed to attenuate TLR/IL-1 sig-
naling which will now be discussed.
A family of eight proteins aptly referred to as the sup-
pressors of cytokine signaling (SOCS), primarily function
to inhibit cytokine signaling. Specifically, SOCS1 is
induced by LPS and CpG-containing DNA, known acti-
vators of the TLR/IL-1 signaling [108]. This led research-
ers to investigate whether SOCS1 played a role in
mitigating TLR/IL-1 signaling. Further investigation
revealed that SOCS1-deficient mice were hypersensitive
to LPS challenge [109,110]. In addition, treatment of
SOCS1-deficient mice with CpG DNA and macrophage-
activating lipopeptide 2 both resulted in the augmented
expression of pro-inflammatory cytokines [109-113].
These findings led investigators to screen for specific
SOCS1 targets within the canonical TLR/IL-1 pathway.
SOCS1 was found to directly target the p65 subunit of
NF-κB leading to its ubiquitination and degradation
[114]. It was also found to target and mitigate the activity
of MAL resulting in the diminished down-stream activa-
tion of NF-κB [115]. Aside from regulating the canonicalTLR/IL-1 pathway, it has also been reported that SOCS1
regulates the alternative MyD88-dependent pathway by
suppressing ASK1. SOCS1 can also alleviate TLR
MyD88-independent signaling as well. As discussed earl-
ier, the activation of MyD88-indepenedent signaling
pathway results in the up-regulation of IFN-β. It has been
shown that SOCS1 represses downstream IFN-β effects on
JAK/STAT signaling [116]. In addition, the JAK2/
STAT5/IL-6 signaling pathway has also been shown
to be repressed by SOCS1 [107]. The ability of SOCS1 to
mitigate the activity of the canonical TLR/IL-1 MyD88-
dependent signaling pathway, the alternative MyD88-
dependent pathway, downstream MyD88-independent sig-
naling, and IL-6 production indicates the significance of
SOCS1 in mediated the innate immune system.
SH2-containing inositol phosphatase, SHIP1, is a
protein tyrosine phosphatase and a potent endogenous
NF-κB inhibitor. SHIP1 has been shown to negatively
regulate several tyrosine kinase-dependent signaling
pathways in myeloid cells, B-lymphocytes, and T-
lymphocytes [117]. The expression of SHIP1 and its
phosphorylation is induced by LPS. This led researchers
to evaluate the role of SHIP1 in TLR/IL-1 signaling and
the discovery that SHIP1 negatively regulates this signal-
ing [118-120]. In fact, this finding may explain the sys-
temic autoimmunity and severe inflammation observed
in SHIP1-deficient mice. In macrophages, TNF-α and IL-
6 production was diminished after LPS stimulation with
SHIP1 over-expression [119]. This observation was sup-
ported by the data gathered from SHIP1 RNA-
interfering studies. In addition, SHIP1 was also found to
inhibit the activation of MAPKs induced by LPS
stimulation.
The immunosuppressive/anti-inflammatory interleu-
kin, IL-10, has also been attributed with mitigating TLR/
IL-1 MyD88-dependent signaling but not MyD88-
independent signaling. Levels of IL-6 were found to be
augmented in the presence of an IL-10R antagonist and
diminished with IL-10 treatment following exposure to
MyD88-dependent signaling activator CpG-containing
DNA. This effect was not seen when treated with PolyI:
C, a MyD88-independent signaling ligand. The dimin-
ished MyD88-dependent signaling associated with the
treatment of IL-10 can be attributed to diminished pro-
tein levels of IRAK4 and TRAF6. In fact, IL-10 antagon-
ism led to prolonged protein levels of IRAK4 and
TRAF6 following LPS treatment in comparison to con-
trols. This observation appears to be the direct result of
increased ubiquitination of IRAK1, IRAK4, and TRAF6
seen with the treatment IL-10. In support of these find-
ings, the effects of IL-10 on MyD88-dependent signaling
were abolished with proteasomal inhibition [121]. It
should also be noted that the expression of IL-10 can be
regulated by the pro-inflammatory protein programmed
Table 1 miRNAs Targets within the TLR/IL-β Signaling
Pathway
TLR Receptors TLR/IL-1β Signaling Molecules
TLR2 miR-105 MyD88 miR-155
TLR4 let-7i MAL miR-145
let-7e IRAK1 miR-146
TRAF6 miR-146
TLR Regulators TAK1 miR-10a
SOCS1 miR-155 TAB2 miR-155
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with siRNA resulted in elevated levels of IL-10 following
LPS stimulation. Similar observations were also made in
PDCD4-deficient mice.
miRNAs regulation of TLR/IL-1β signaling
Crucial for proper immune system function, TLR/IL-1
signaling is under stringent regulation. This adept regu-
lation is required to ensure proper host defense while
mitigating the deleterious effects of the inflammation
process. Previously discussed regulators like SOCS1 and
SHIP1 can inhibit various aspects of this shared pathway
via transcription and post-translational mechanisms, and
we will now discuss the fine-tuned regulation of the
TLR/IL-1 pathway by miRNAs via miRNAs-directed
mRNAs translation repression or cleavage [6,7].
miRNAs modulation of TLRs/IL-1R
The most obvious way that miRNAs can affect TLR/IL-1
signaling is by altering the expression of the receptors.
However, examination of TLRs and IL-1R for highly con-
served miRNAs consensus binding regions with target
prediction software like TargetScan and PicTar have
yielded few results. This may be the result of species-
specific regulation of TLRs and IL-1R by poorly con-
served sites or it might be that the critical role of TLRs
and IL-1R in immunity facilitates the need for tight tran-
scriptional control or the need for constitutive expres-
sion. With that said, the regulation of TLR-2 and −4 by
miRNAs has been observed. The direct association of
miR-105 with TLR2 mRNAs has been witnessed while
working in human oral keratinocytes, while the regula-
tion of TLR4 expression by let-7i in human biliary epi-
thelial cells and by let-7e in macrophages has been
reported (Table 1) [122-124]. miR-105 association with
TLR-2 mRNAs was predicted by bioinformatics studies
and the binding site was confirmed using a luciferase re-
porter assay. Luciferase activity was diminished in the
cells co-transfected with TLR-2 3’UTR binding site se-
quence vectors and miR-105 mimics. This effect was not
seen in the cells co-transfected with scrambled vector
controls and the mimic, indicating binding site specifi-
city. Furthermore, the presence of miR-105 inhibitors led
to elevated TLR-2 expression detected by Western blots
[124]. Similar to miR-105, let-7i was demonstrated to
directly bind to TLR4 mRNAs detected by a luciferase
reporter. Further experimentation with RT-PCR showed
that let-7i mimics, inhibitors, and scrambled controls did
not alter TLR4 mRNAs levels. This finding suggests that
let-7i controls TLR4 protein expression by translation re-
pression and not via TLR4 mRNA degradation. This was
further supported when infection with Cryptosporidium
parvum led to the up-regulation of TLR4 protein expres-
sion but not its mRNAs. This alteration in TLR4 proteinexpression could be diminished or augmented when cells
were transfected with either let-7i mimic or inhibitors re-
spectively [123]. Similar results were seen in macro-
phages with the expression of let-7 [122]. However,
unlike with let-7i, it was clearly illustrated that TLR4
mRNAs levels were suppressed after treatment with a
let-7e mimic for 24 hours. Furthermore, when the
macrophages were treated with a let-7e inhibitor, TLR-4
mRNAs expression was increased by 3.5 folds after 24
hours [122]. These studies reveal the possible mitigation
of TLR expression by miRNAs. It should be noted that
no miRNAs association with IL-1R mRNAs has been
reported thus far.
miRNAs regulation of TLR/IL-1β adaptor molecules
Despite the limited number of experimentally verified
miRNAs that interact with TLR/IL-1β receptors, there
are abundant instances of miRNAs targeting TLR/IL-1
adaptor molecules. This encompasses miRNAs that tar-
get multiple adaptors within the TLR/IL-1 pathway and
those that target individual proteins. As discussed earlier,
MyD88 is an integral adaptor molecule in proper TLR/
IL-1 signaling, functioning as the signal transducer for
IL-1R and all TLRs, except TLR-3. Therefore, it should
not be surprising that this prominent signaling protein is
targeted by miRNAs. Predicted by TargetScan and ex-
perimentally verified with luciferase reporter assays, it
has been clearly demonstrated that miR-155 directly reg-
ulates the expression of MyD88. Additionally, the trans-
fection of cells with miR-155 mimics revealed that
MyD88 protein expression was modulated in a time and
dose-dependent manner. To determine the method of
miRNAs repression, RT-PCR was performed following
mimic treatment. This resulted in no change in MyD88
mRNAs levels, suggesting that miR-155 modulates
MyD88 protein expression by mRNAs translation
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adaptor protein MAL, which facilitates MyD88 inter-
action with TLR-2 and TLR-4, has also been found to be
regulated by miRNAs. Predicted to be targeted by miR-
145, this interaction was confirmed by luciferase reporter
assays in human embryonic kidney 293 (HEK293) cells.
Western blots were then carried out following mimic or
inhibitor transfection of bone marrow cells which veri-
fied that MAL protein expression was diminished and
augmented, respectively. Unfortunately, mRNAs levels
were not examined so the exact mechanism of miRNAs
repression cannot be cited. Acting downstream and asso-
ciating with MyD88, IRAK1 is essential to TLR/IL-1 sig-
naling and has been identified as a target of miR-146a/b.
Again, this association was predicted utilizing online
software and then confirmed with luciferase reporter
assays [126]. This interaction was further confirmed by
another group with the transfection of miR-146a mimics
and inhibitors in macrophages [127]. IRAK4 has yet to
have miRNAs association experimentally identified. This
may be the result of the fact that it plays a role in, but is
not essential to, TLR signaling. Despite this, the possibil-
ity of miRNAs interactions should not be ruled out until
further investigation is concluded. Functioning down-
stream of the IRAKs, TRAF6 has been confirmed to be
targeted by miR-146. Luciferase reporter assays with
TRAF6 3’UTR-containing vectors verified this associ-
ation. Online prediction algorithms were then used to
identify the exact binding site so that a mutated vector
could be constructed. The use of this mutant in lucifer-
ase reporter assays confirmed binding site specificity.
Mitigation of TRAF6 protein expression was then veri-
fied by Western blot following mimic and inhibitor
transfection [126,127]. Downstream of TRAF6 is TAK1
which functions to activate the IKK complex. The pre-
diction of a conserved miRNA-10a binding site by Tar-
getScan within the 3’UTR of TAK1 was confirmed in
HEK293 cells [128]. Furthermore, it was experimentally
demonstrated that TAK1 mRNAs and protein was ele-
vated with miR-10a knockdown in human aortic endo-
thelial cells by qRT-PCR and Western blot, respectively.
Facilitating the protein-protein interaction of TRAF6
and TAK1 is TAB2. This important adaptor has been
identified to be modulated by miR-155. A predicted asso-
ciation by TargetScan, the miR-155:TAB2 interaction
was proven through Western blot, qRT-PCR, and lucifer-
ase reporter assay results. This repression was supported
by the similar findings by another independent research
group [129]. The IKK complex is located downstream of
TAK1 and contains 3 subunits. Two of those subunits,
IKK-α and IKK-β, have been found to be under miRNAs
regulation. IKK-α is mediated by miR-223, miR-15a, and
miR-16 while IKK-β is targeted by miR-199. The associ-
ation between IKK-α and all three miRNAs wereconfirmed individually with luciferase reporter assays by
creating constructs mutated for each specific miRNAs
binding site. In addition, transfection with mimics for all
three miRNAs results in diminished Iκk-α protein levels
in human cervical cancer (HeLa) cells and macrophages.
As predicted by PicTar, IKK-β contains three putative
miR-199 binding sites. A luciferase reporter assay was
utilized to confirm this targeting while the use of mimics
and inhibitors demonstrated that IKK-β protein levels
could be mitigated. Once the IKK complex phosphory-
lates IκB, NF-κB is freed from repression to translocate
to the nucleus. As mentioned earlier, NF-kB contains
two subunits p50 and p65. NFκB1 mRNAs, which is
cleaved to form the mature NF-κB subunit p50, has been
found to be directly modulated by miR-9. This subunit is
significant in the transactivation of the p65 subunit
allowing NF-κB to translocate to the nucleus. The direct
interaction between miR-9 and NFκB1 was again estab-
lished with luciferase reporter assays while overexpres-
sion of miR-9 in monocytes resulted in diminished
NFκB1 protein levels. Unique to the MyD88-
independent pathway, IKKε has also been identified as a
target of miR-155. Predicted by the prediction algo-
rithms, TargetScan and RNAhybrid, direct association
was experimentally confirmed by luciferase reporter
assays. Revealed by qRT-PCR, the mRNAs levels of IKKε
were found to be altered by the transfection of human
gastric epithelial GES-1 cells with miR-155 mimics. This
indicates that miR-155 alters IKKε protein expression by
mRNAs cleavage.
miRNAs mitigation of TLR/IL-1 signaling
regulators
The activity of signaling regulators must be closely moni-
tored to ensure adequate activity and suppression of the
TLR/IL-1 cascade when necessary. Therefore, the critical
nature of these regulatory proteins perpetuates their po-
tential for modulation by miRNAs. As mentioned previ-
ously, SOCS1 plays an integral role in regulating TLR/
IL-1 signaling by targeting several proteins within the
pathway. The ability of miRNAs to modulate SOCS1 ex-
pression would therefore have a significant effect on
TLR/IL-1 signaling. In fact, several groups have reported
that SOCS1 expression can be directly mediated by miR-
155 [130-132]. Direct association between SOCS1
mRNAs and miR-155 was confirmed using luciferase re-
porter constructs containing the native 3’ UTR of SOCS1
mRNAs. Using the target prediction software PicTar, the
miR-155 binding site sequence was identified and the na-
tive 3’ UTR of SOCS1 mRNAs was mutated to verify
binding-site specificity. Also, an arbitrary miRNA not
predicted to bind to SOCS1 was tested to verify miR-155
specificity [130,131]. This direct association was then
further verified with a gel shift mobility assay that
Virtue et al. Journal of Hematology & Oncology 2012, 5:66 Page 12 of 17
http://www.jhoonline.org/content/5/1/66examined the ability of miR-155 to form duplexes with
the predicted binding site sequence within the native 3’
UTR of SOCS1 mRNAs. Again, a mutated sequence was
used to verify the binding site while anti-sense miR-155
was utilized as a positive control [131]. With association
clearly demonstrated by the previous experiments, West-
ern blot analysis was performed to verify that SOCS1
protein expression was mitigated. Transfection with
miR-155 mimics or with miR-155-containing adeno-
viruses both impaired the protein expression of SOCS1
in a similar fashion to SOCS1 siRNAs [131,132]. These
results were further supported by observations in miR-
155 deficient mice, which showed elevated SOCS1 ex-
pression in T-cells [130]. Notably, SOCS1 mRNAs levels
remained unaffected in the presence of miR-155 mimics,
miR-155 inhibitors, or in miR-155-deficient mice. This
indicates that SOCS1 expression is modulated by miR-
155 via translational repression but not via mRNAs
degradation.
miR-155 not only plays a critical role in SOCS1 expres-
sion but also has been confirmed in epithelial cells,
macrophages, and myeloid cells to regulate SHIP1 ex-
pression [133-135]. Bioinformatics exploration with the
target prediction software TargetScan revealed a highly
conserved miR-155 binding site in SHIP1’s 3’UTR. In
fact, this was the only highly conserved miRNAs binding
site within the 3’UTR of SHIP1 [133]. Direct association
was experimentally confirmed with a luciferase report
assay where 293 T-cells were co-transfected with miR-
155 mimics and wild-type SHIP1 3’UTR reporter
plasmids. Those cells transfected with the mimics dis-
played impaired chemoluminescence in comparison to
those transfected with the control miRNAs [134,135].
Predictably, cells transfected with scrambled SHIP1
3’UTR reporter plasmids showed no variability in che-
moluminescence with either miR-155 mimics or controls
[133,134]. In a separate study where cystic fibrosis IB3
epithelial cells have diminished levels of SHIP1 mRNAs
compared to normal IB3 epithelial cells, treatment of fi-
brosis IB3 epithelial cells with miR-155 inhibitors led to
increased luciferase activity associated with normal IB3
SHIP1 levels [135]. With miR-155:SHIP1 association
confirmed, Western blots were performed to verify a
change in SHIP1 protein levels. Utilizing miR-155-
containing vectors it was demonstrated that SHIP1 ex-
pression was reduced 2.3 folds. Additionally, the use
miR-155 mutant vectors showed no significant fold
changes, verifying miR-155 specificity [133]. Further-
more, observation of miR-155-deficient macrophages
revealed elevated SHIP-1 protein expression in compari-
son with wild-type controls [133,134]. RAW 264.7 cells
transfected with wild-type miR-155 vectors led to an ap-
proximately 50% reduction in SHIP1 mRNAs when com-
pared to the flag control. This effect was not seen intransfections with miR-155 mutant vectors [133]. These
findings were supported by the data collected from a
separate investigator conducting transfections with miR-
155 mimics and inhibitors. Again, the expression of
SHIP1 mRNAs was diminished by approximately 50%
with miR-155 overexpression while inhibition of miR-
155 function led to an equivalent increase [134]. Taken
together, these dramatic changes in SHIP1 mRNAs indi-
cate that miRNA-155 regulates SHIP1 expression by
mRNAs degradation.
IL-10 is a prototypical anti-inflammatory cytokine
which has been shown to affect IRAK4 and TRAF6 ubi-
quitination as described earlier. Utilizing three miRNAs
target prediction programs, miR-106a was identified as
having a binding-site in IL-10’s 3’UTR. Experiments con-
ducted in B lymphoma lymphoblast-like Raji cells with
miR-106a mimics resulted in a dose-dependent reduction
of IL-10 protein in the culture supernatant. IL-10
mRNAs levels were also reduced in a dose-dependent
manner when examined by qRT-PCR. The target site
within the 3’UTR of IL-10 mRNAs was then confirmed
in T cell leukemia Jurkat cells and Raji cells with
luciferase reporter assays. These results indicate that IL-
10 expression is capable of being transcriptionally
regulated by miR-106a [136]. Mentioned previously, pro-
inflammatory protein PDCD4 is capable of repressing
IL-10 and therefore the repression of PDCD4 by miR-
NAs would in effect increase IL-10’s TLR/IL-1 regulatory
activity. As it is, miR-21 has been found to target
PDCD4. Transfecting RAW264.7 cells with miR-21
inhibitors mitigated the inhibitory effects of PDCD4 on
IL-10 typically seen following LPS stimulation. Similar
findings were found when competitive oligonucleotides
that were specific to the miR-21 binding site in the
PDCD4 3’UTR were used [137].
miRNAs expression modulation by
TLR/IL-1 signaling
As we have discussed, several miRNAs play an important
role in regulating the TLR/IL-1 signaling pathway. Inter-
estingly, recent findings have revealed that the activation
and induction of this very important pathway can
modulate the expression of several miRNAs [138]. Among
them are some of the same miRNAs that regulate TLR/IL-
1 signaling, indicating that these miRNAs participate in ei-
ther positive or negative feedback mechanisms. The first
miRNA identified to be modulated by TLR/IL-1 signaling
was miR-146. Its expression was shown to be rapidly
augmented following the exposure of human acute
monocytic leukemia THP-1 cells to LPS. Further
studies have shown that miR-146 can also be induced
by ligands for TLR-2, -3, and −5 in macrophages,
bone marrow-derived monocytes, and T-cells [139].
In addition, the expression of miR-146 was shown to
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ability of TLR/IL-1 signaling to induce miR-146 ex-
pression has been shown to be NF-κB-dependent.
Taken into account that experiments with over-
expressing miR-146 epithelial cells and fibroblasts
resulted in a reduction of IL-1-induced cytokine ex-
pression, and that miR-146 is known to target the critical
TLR/IL-1 signaling molecules IRAK1 and TRAF6, one can
conclude that miR-146 is capable of mitigating a TLR/IL-1
inflammatory response in a negative feedback manner.
One of the most extensively characterized miRNAs,
miR-155, has been proven to be induced by several TLR
ligands in mouse bone marrow-derived macrophages.
Specifically, ligands for TLR-2, -3, -4, and −9, were found
to augment miR-155 expression [140]. Interestingly, this
indicates that both the MyD88-dependent and MyD88-
independent pathway can augment miR-155 expression.
Mechanistically, both TLR/IL-1 downstream transcrip-
tion factors, NF-κB and AP-1, have been shown to facili-
tate the transcription activation of the B-cell integration
cluster (Bic), the gene that encodes for miRNA-155
[140,141]. This data clearly shows that miR-155 expres-
sion is augmented by TLR/IL-1 activity while direct miR-
155 targeting of TLR/IL-1 signaling molecules MyD88,
TAB2, and IKKε suggests that miR-155 can
suppress TLR/IL-1 signaling by a negative feedback
mechanism. Interestingly, miRNA-155 has also been
credited with reciprocally facilitating TLR/IL-1 signal-
ing. Experimentally, over-expression of miR-155 in the
bone marrow compartment of adult mice led to myelo-
proliferation typically observed following LPS injection
[142]. This may be explained by the fact that miR-155
is known to directly repress the activities of TLR/IL-
1 signaling inhibitors SHIP1 and SOCS1. In
this case, miR-155 would participate in a positive-
feedback loop.
These differing results suggest several key points about
miRNAs regulation. First, miRNAs activity and expres-
sion is heavily dependent on specific cell types; second,
the preferential targeting of individual mRNA may be
highly dependent on the expression of those mRNA
or other unforeseen factors; and third, that seeming
contradictive targeting may in fact be avoided by pre-
cisely orchestrated timing. Taking these considerations
into account the targeting of SOCS1 and SHIP1 by
miRNA-155 may initially be required to augment
novel TLR/IL-1 signal transduction when an immune
response is required. However, the perpetuation of
this signal may need to be suppressed after a specific
duration of inflammation initiation to prevent detri-
mental effects. Under these conditions the repression
of adaptor molecules MyD88, TAB2, and IKKε would
be required.miR-9 has also been shown to be augmented by TLR/
IL-1 activity in monocytes and granulocytes [143,144].
While mature miR-9 can be produced from three unique
primary transcripts encoded by three distinct genes, LPS
treatment only induced one of these primary transcripts,
miR9-1. The promoter region of the chromosome 1 open
reading frame 61 (C1orf61) locus, which generates this
particular primary transcript, contains consensus bind-
ing sites for known LPS-sensitive transcription factors
like NF-κB. This evidence suggests that rapid activa-
tion of the TLR/IL-1 signaling pathway leads to the
induction of miR-9 through NF-κB-directed transcrip-
tion of the miR9-1 transcript. In fact, the necessity of
NF-κB in miR-9 induction was confirmed with the
use of several different NF-κB inhibitors. Furthermore,
inhibitors for p38 and JNK demonstrated no inhibitory
effect on miR-9 induction following TLR/IL-1 signal-
ing activation, further suggesting NF-κB’s involvement.
Therefore, miR-9 can be described as a negative feed-
back regulator of TLR/IL-1 signaling since it targets
the NF-κB subunit 50 as previously mentioned [143].
Another miRNAs shown to be elevated by TLR/IL-1
signaling in B-cells, cholangiocytes (epithelial cells
of the bile duct), macrophages, and inflamed lung tis-
sue is miR-21 [137,145-147]. This effect was abolished
in immortalized, bone-marrow derived monocytes
(BMDMs) deficient in MyD88 but was only slightly
diminished in TRIF-deficient BMDMs. This suggests that
the augmentation of miR-21’s expression is NF-κB-
dependent. Further investigation revealed that the pro-
moter of miRNA-21 contains a predicted NF-κB binding
site. Its significance was confirmed in mouse embryonic
fibroblasts that were deficient in the NF-κB p65 subunit.
In these cells miRNA-21 levels could not be induced by
LPS. Following LPS stimulation in RAW264.7 macro-
phages, the levels of miR-21 are not significantly induced
until 4 hours and continue to increase until 24 hours.
This observation is in accordance with the fact that
PDCD4 expression immediately increases following LPS
treatment but then is diminished at 4 hours and abol-
ished at 24 hours [137]. Clearly, the expression of
PDCD4 following LPS treatment is dependent on miR-
21 expression. Furthermore, the reduction of PDCD4 by
miR-21 explains the augmented levels of IL-10 observed
after LPS treatment. The induced expression of miR-21
by TLR/IL-1 signaling results in a negative feedback
loop by reducing PDCD4, causing greater IL-10 activity.
Conclusion
The TLR/IL-1 signaling pathway is critical to proper im-
mune functioning. Hyper-activation has been associated
with several autoimmune and chronic pathologies while
hypo-activation leaves the host highly susceptible to in-
fection. Therefore, it is not surprising that this signaling
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physical interactions, conformational changes, regulatory
proteins, as well as ubiquitin and proteasomal degrad-
ation. We have also discussed the activity of miRNAs in
further modulating this signaling system. Interestingly,
many of these exact miRNAs are also induced by the ac-
tivation of the TLR/IL-1 signaling cascade, indicating a
mutual regulation between miRNAs and TLR/IL-1 path-
way via a complex positive- and negative-feedback loop
system [148]. The role of these participating miRNAs
needs to be closely evaluated as they hold vast potential
as novel therapeutics.
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